Investigational drug · Phase 3
Venglustat
Also called: GZ402671
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
20
Any phase or sponsor naming "Venglustat"
First trial start
2017
Jan 4, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Venglustat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fabry Disease
- Gaucher's Disease Type III
- Gaucher Disease Type 1
- Gaucher Disease Type 3
Approved drugs for the same conditions: Fabry disease · Gaucher disease · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Venglustat" as an intervention, largest first.
- A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD PatientsPivotal-lookingTerminated
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03523728 · 478 participants · Start Oct 4, 2018 · Primary completion Aug 3, 2021
Drug: Venglustat; Placebo · For: Polycystic Kidney, Autosomal Dominant
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 95 sites in all
- A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene MutationPivotal-lookingTerminated
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02906020 · 273 participants · Start Dec 15, 2016 · Primary completion Dec 18, 2020
Drug: venglustat GZ/SAR402671; Placebo · For: Parkinson's Disease
Sites: Scottsdale, Arizona; La Jolla, California; Palo Alto, California · 52 sites in all
- A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05206773 · 122 participants · Start Mar 11, 2022 · Primary completion Dec 17, 2025
Drug: Venglustat (GZ402671); Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 50 sites in all
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05280548 · 104 participants · Start May 3, 2022 · Primary completion May 22, 2026
Drug: Venglustat (GZ402671); Agalsidase alfa and 2 more · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 54 sites in all
- A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2Pivotal-lookingTerminated
Genzyme, a Sanofi CompanySanofi (SNY)
NCT04221451 · 75 participants · Start Jun 29, 2020 · Primary completion Dec 26, 2024
Drug: venglustat GZ402671; placebo · For: Tay-Sachs Disease; Sandhoff Disease
Sites: Los Angeles, California; Atlanta, Georgia; Bethesda, Maryland · 23 sites in all
SanofiSanofi (SNY)
NCT06418607 · 65 participants · Start Jun 23, 2020 · Primary completion Jul 13, 2020
Drug: Venglustat; Venglustat · For: Healthy Volunteers
Sites: Miami, Florida; Saint Paul, Minnesota
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01674036 · 63 participants · Start Aug 2012 · Primary completion Jan 2013
Drug: Genz-682452; Placebo · For: Healthy Volunteer
Sites: Austin, Texas
- Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05222906 · 43 participants · Start Apr 18, 2022 · Primary completion Oct 2, 2025
Drug: Venglustat; imiglucerase · For: Gaucher's Disease Type III
Sites: New Haven, Connecticut; Iowa City, Iowa; Dallas, Texas · 22 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT01710826 · 36 participants · Start Oct 2012 · Primary completion Feb 2013
Drug: Genz-682452; Placebo · For: Healthy
Sites: Austin, Texas
SanofiSanofi (SNY)
NCT05718258 · 26 participants · Start Jan 18, 2023 · Primary completion Jan 29, 2024
Drug: Venglustat (GZ402671) · For: Hepatic Function Abnormal
Sites: Rialto, California; Miami, Florida; Saint Paul, Minnesota · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Target engagement without clinical benefit: a systematic review, mechanism-concordant meta-analysis, and research agenda for Parkinson's disease immunotherapy.
Zhou X, Richard SA, Lan Z, et al. · Immunotherapy 2026
- Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.
Tifft CJ, Batsu I, Giugliani R, et al. · Genet Med 2026
- Underlying Mechanisms of GBA1 in Parkinson's Disease and Dementia with Lewy Bodies: Narrative Review.
Bougea A · Genes (Basel) 2025
- Historical Control Analysis Demonstrates Greater Long-Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease.
Germain DP, DasMahapatra P, Liu S, et al. · Mol Genet Genomic Med 2025
- Precision medicine and music therapy for Parkinson's Disease.
Li-Hua P, Jallow L, Tan Y, et al. · Clin Park Relat Disord 2025
- Drug-drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics.
Li L, Zhang YY, Sharma J, et al. · Br J Clin Pharmacol 2025
Also in development for Fabry Disease
- LucerastatPhase 32 trials
Idorsia Pharmaceuticals Ltd. · Fabry Disease
- 4D-310Phase 22 trials
4D Molecular Therapeutics · Fabry Disease
- AMT-191Phase 21 trial
UniQure Biopharma B.V. · Fabry Disease
- EXG110Phase 21 trial
Guangzhou Jiayin Biotech Ltd · Fabry Disease
- ST-920Phase 21 trial
Sangamo Therapeutics · Fabry Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.